DekaBank Deutsche Girozentrale Buys 6,997 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 98.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,094 shares of the medical research company's stock after acquiring an additional 6,997 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in Charles River Laboratories International were worth $3,333,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC lifted its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock valued at $28,000 after acquiring an additional 74 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International in the third quarter worth about $37,000. Operose Advisors LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $42,000. Covestor Ltd boosted its stake in shares of Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company's stock worth $49,000 after acquiring an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after acquiring an additional 112 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 over the last three months. Company insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore ISI upped their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. upped their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an "overweight" rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research report on Friday, March 1st. UBS Group increased their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Finally, Citigroup boosted their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.23.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $5.08 during mid-day trading on Friday, hitting $241.34. The company's stock had a trading volume of 389,716 shares, compared to its average volume of 437,029. The company has a market capitalization of $12.43 billion, a price-to-earnings ratio of 26.20, a P/E/G ratio of 1.93 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The stock has a fifty day moving average of $252.64 and a 200-day moving average of $220.13.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company's revenue was down 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.98 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).